BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, focused on the development of targeted small molecule inhibitors designed to treat various forms of cancer. Leveraging its innovative drug discovery platform, the company aims to address unmet medical needs in oncology through precision medicine approaches. With a robust pipeline of therapeutic candidates, BridgeBio is strategically positioned to advance an array of treatments from preclinical stages to clinical trials, targeting specific genetic drivers of cancer for improved patient outcomes.